Holen Sie sich die Stockscreener-App
4.465
3.45%
-0.175
Schlusskurs vom Vortag:
$4.64
Offen:
$4.56
24-Stunden-Volumen:
834.49K
Relative Volume:
0.30
Marktkapitalisierung:
$1.23B
Einnahmen:
$6.31M
Nettoeinkommen (Verlust:
$-99.93M
KGV:
-12.60
EPS:
-0.3544
Netto-Cashflow:
$-85.14M
1W Leistung:
-1.97%
1M Leistung:
+1.59%
6M Leistung:
+33.33%
1J Leistung:
+163.53%
1-Tages-Spanne:
$4.465
$4.60
1-Wochen-Bereich:
$4.44
$4.70
52-Wochen-Spanne:
$1.05
$6.02
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Firmenname
Taysha Gene Therapies Inc
Sektor
Branche
Telefon
(214) 612-0000
Adresse
3000 PEGASUS PARK DRIVE, DALLAS
Compare TSHA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
4.49 | 1.27B | 6.31M | -99.93M | -85.14M | -0.3544 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.40 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.30 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
731.90 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.08 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
295.53 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | Raymond James | Strong Buy |
| 2025-07-11 | Eingeleitet | BofA Securities | Buy |
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-04-09 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-01 | Herabstufung | Jefferies | Buy → Hold |
| 2023-01-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | Herabstufung | Goldman | Buy → Neutral |
| 2022-03-09 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-03-01 | Eingeleitet | Wells Fargo | Overweight |
| 2022-02-18 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-12-16 | Eingeleitet | Guggenheim | Buy |
| 2021-07-16 | Eingeleitet | Needham | Buy |
| 2021-06-24 | Eingeleitet | Truist | Buy |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-06-09 | Eingeleitet | Wedbush | Outperform |
| 2021-06-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-05-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-05-11 | Fortgesetzt | Jefferies | Buy |
| 2021-02-24 | Eingeleitet | William Blair | Outperform |
| 2021-01-05 | Eingeleitet | Oppenheimer | Outperform |
| 2020-10-19 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-10-19 | Eingeleitet | Goldman | Buy |
| 2020-10-19 | Eingeleitet | Jefferies | Buy |
| 2020-10-19 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Taysha Gene Therapies Inc Aktie (TSHA) Neueste Nachrichten
TSHA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Taysha Gene faces earnings test as Rett trial advances By Investing.com - Investing.com South Africa
Taysha Gene faces earnings test as Rett trial advances - Investing.com
Taysha Gene Therapies (NASDAQ:TSHA) Earns Buy Rating from Needham & Company LLC - MarketBeat
TSHA: Needham Reiterates Buy Rating with Price Target Maintained | TSHA Stock News - GuruFocus
TSHA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Taysha Gene Therapies, Inc. (TSHA): Analyst Ratings Signal Potential 140% Upside In Biotech Stock - DirectorsTalk Interviews
Insider sale activity at Taysha Gene Therapies (NASDAQ: TSHA) - Stock Titan
TSHA Should I Buy - Intellectia AI
What is the next catalyst for Taysha Gene Therapies Inc.Long Setup & Precise Buy Zone Identification - mfd.ru
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Will Taysha Gene Therapies Inc. benefit from AI trendsTrade Entry Summary & Detailed Earnings Play Alerts - mfd.ru
How liquid is Taysha Gene Therapies Inc. stock2025 Breakouts & Breakdowns & Technical Pattern Alert System - mfd.ru
RTW INVESTMENTS, LP Reduces Stake in Taysha Gene Therapies Inc - GuruFocus
Taysha Gene Therapies, Inc. (TSHA) Stock Analysis: Unpacking a 129.65% Potential Upside - DirectorsTalk Interviews
CEO Moves: How cyclical is Taysha Gene Therapies Incs revenue stream2025 Winners & Losers & Community Verified Trade Alerts - baoquankhu1.vn
Needham Reiterates Taysha Gene Therapies (TSHA) Buy Recommendation - MSN
GSA Capital Partners LLP Increases Holdings in Taysha Gene Therapies, Inc. $TSHA - MarketBeat
Taysha Gene Therapies (TSHA) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Rate Cut: What is the next catalyst for Taysha Gene Therapies IncEntry Point & Growth Oriented Trade Recommendations - baoquankhu1.vn
Commit To Buy Taysha Gene Therapies At $2.50, Earn 16.8% Annualized Using Options - Nasdaq
Portfolio Recap: How does NBBK perform in inflationary periodsJuly 2025 Chart Watch & Consistent Return Investment Signals - baoquankhu1.vn
TSHA PE Ratio & Valuation, Is TSHA Overvalued - Intellectia AI
Taysha Gene Therapies, Inc. (TSHA) Investor Outlook: Analyst Consensus Reveals 136.56% Potential Upside - DirectorsTalk Interviews
Does Taysha Gene Therapies Inc. have declining or rising EPSQuarterly Earnings Summary & Fast Entry Momentum Alerts - mfd.ru
Here’s what analysts are saying about Taysha Gene Therapies (TSHA) - MSN
Can Taysha Gene Therapies Inc. outperform under higher oil pricesGDP Growth & Weekly Return Optimization Plans - mfd.ru
Taysha Gene Therapies, Inc. $TSHA Holdings Trimmed by Tybourne Capital Management HK Ltd. - MarketBeat
Is Taysha Gene Therapies Inc undervalued by DCF analysisJuly 2025 Outlook & Fast Moving Stock Trade Plans - baoquankhu1.vn
Retail Trends: What is the next catalyst for Taysha Gene Therapies IncPortfolio Gains Summary & High Accuracy Buy Signal Tips - baoquankhu1.vn
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule - TipRanks
Taysha Gene Therapies (TSHA) Awards Restricted Stock Units to Ne - GuruFocus
Did Rett Trial Milestones Just Shift Taysha Gene Therapies' (TSHA) Gene Therapy Approval Path Narrative? - Yahoo Finance
Taysha Gene Therapies, Inc. (TSHA) gains Wells Fargo’s support on Rett syndrome program progress - MSN
Taysha’s REVEAL Trial Progress Puts Rett Gene Therapy And Valuation In Focus - Sahm
Cell And Gene Therapy Enters ‘Disciplined Growth Cycle’ As Commercial Momentum Builds - Citeline News & Insights
Taysha Gene Therapies, Inc. (TSHA) Gains Wells Fargo’s Support on Rett Syndrome Program Progress - Insider Monkey
Taysha Gene Therapies, Inc. (TSHA) Gains Wells Fargo's Support on Rett Syndrome Program Progress - Finviz
Institution Moves: Does Taysha Gene Therapies Inc have strong fundamentals2025 Retail Activity & Stepwise Swing Trade Plans - baoquankhu1.vn
Taysha Gene Therapies, Inc. $TSHA Shares Sold by SG Americas Securities LLC - MarketBeat
Activity Recap: How cyclical is Taysha Gene Therapies Incs revenue streamWeekly Stock Report & Precise Trade Entry Recommendations - baoquankhu1.vn
Pivotal Trial for Taysha's Rett Syndrome Gene Therapy TSHA-102 Doses First Patient - CGTLive®
Taysha Doses First Patient in Pivotal Trial for Rett Syndrome Gene Therapy TSHA-102, Aligns With FDA on BLA Plans - NeurologyLive
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
10 Best Strong Buy Stocks to Invest In Under $5 - Insider Monkey
Here’s What Analysts Are Saying About Taysha Gene Therapies (TSHA) - Insider Monkey
Taysha Gene Therapies (NASDAQ:TSHA) CEO Sells $649,747.75 in Stock - MarketBeat
Insider Selling: Taysha Gene Therapies (NASDAQ:TSHA) CEO Sells 41,312 Shares of Stock - MarketBeat
Insider Selling: Taysha Gene Therapies (NASDAQ:TSHA) Insider Sells 26,918 Shares of Stock - MarketBeat
Kamran Alam Sells 78,968 Shares of Taysha Gene Therapies (NASDAQ:TSHA) Stock - MarketBeat
Finanzdaten der Taysha Gene Therapies Inc-Aktie (TSHA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Taysha Gene Therapies Inc-Aktie (TSHA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Alam Kamran | CHIEF FINANCIAL OFFICER |
Feb 04 '26 |
Sale |
4.52 |
1,655 |
7,481 |
1,442,131 |
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):